EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Implementation of a Pharmacogenetic Strategy for Statin Therapy in the Spanish National Health System: A Systematic Review and Regulatory Framework Analysis

Alba Sánchez-Redondo, Levin Thomas, Francisco Arias-Aragón, José M. Ramiro-Lozano, Enrique José Gamero-de-Luna, Carmen Mata-Martín, Adrián Llerena

Pharmaceuticals · 29.10.2026 · 19 (11) · 1701

DOI: 10.3390/ph19111701 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pharmaceuticals, online erschienen am 29.10.2026. Verfasst von Alba Sánchez-Redondo und 6 weiteren Autor:innen. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Unión Europea, Fondo Europeo de Desarrollo Regional.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Statins are the first-line lipid-lowering therapy, but their use is limited by interindividual variability in efficacy and safety, particularly statin-associated muscle symptoms. This systematic review aimed to identify pharmacogenetic biomarkers related to statin response, compare them with regulatory recommendations, and propose a candidate pharmacogenetic panel for future clinical validation and implementation studies.

Methods

A PRISMA-based systematic review identified 78 eligible studies. A novel composite consistency index integrated the frequency and direction of reported associations across studies, weighted by the methodological quality of the evidence. Identified pharmacogenetic biomarkers were compared with international pharmacogenetic guidelines and Spanish regulatory recommendations to support prioritization. Results:SLCO1B1 showed the strongest and most consistent evidence, particularly for simvastatin-induced myotoxicity, whereas ABCG2 demonstrated the most consistent evidence for rosuvastatin. Evidence linking genetic biomarkers to atorvastatin-related adverse reactions was heterogeneous, while CYP2C9 was associated with fluvastatin response. Other biomarkers were positively associated with statin-related adverse reactions; however, the available evidence remains limited.

Conclusions

International guidelines and Spanish regulatory resources revealed substantial concordance despite differences in biomarker inclusion and therapeutic recommendations. Based on the available evidence, a candidate pharmacogenetic biomarker panel is proposed for future implementation studies in personalized statin therapy. SLCO1B1 and ABCG2 emerged as the biomarkers with the strongest and most consistent support across published evidence, regulatory recommendations, and established statin transport pathways. CYP2C9 was also identified as a potentially relevant implementation biomarker; however, the supporting evidence was more limited. Additional biomarkers showed positive associations with statin-related adverse reactions; however, further validation is required.

Förderung

  • Instituto de Salud Carlos III
  • Unión Europea, Fondo Europeo de Desarrollo Regional

Zitieren

APA

Sánchez-Redondo, A., Thomas, L., Arias-Aragón, F., Ramiro-Lozano, J. M., Gamero-de-Luna, E. J., Mata-Martín, C., & Llerena, A. (2026). Implementation of a Pharmacogenetic Strategy for Statin Therapy in the Spanish National Health System: A Systematic Review and Regulatory Framework Analysis. Pharmaceuticals, 19(11), 1701. https://doi.org/10.3390/ph19111701

Vancouver

Sánchez-Redondo A, Thomas L, Arias-Aragón F, Ramiro-Lozano JM, Gamero-de-Luna EJ, Mata-Martín C, et al. Implementation of a Pharmacogenetic Strategy for Statin Therapy in the Spanish National Health System: A Systematic Review and Regulatory Framework Analysis. Pharmaceuticals. 2026;19(11):1701. doi:10.3390/ph19111701

BibTeX
@article{SnchezRedondo2026,
  author = {Sánchez-Redondo, Alba and Thomas, Levin and Arias-Aragón, Francisco and Ramiro-Lozano, José M. and Gamero-de-Luna, Enrique José and Mata-Martín, Carmen and Llerena, Adrián},
  title = {Implementation of a Pharmacogenetic Strategy for Statin Therapy in the Spanish National Health System: A Systematic Review and Regulatory Framework Analysis},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1701},
  doi = {10.3390/ph19111701}
}
Kostenlos starten →